30 Participants NeededMy employer runs this trial

Hydration for Reducing Side Effects of GLP-1 RA Therapy

Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: State University of New York at Buffalo
Must be taking: GLP-1RA
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This is a 17 - week study consisting of a one - week run - in period and a 16 - week intervention. The 16 - week pilot interventions aims to increase hydration in those beginning GLP - 1 RA therapy. Investigators aim to increase hydration to potentially decrease side effect severity, amount of side effects, and drug discontinuation associated with GLP - 1 RA therapy. The investigators are piloting to assess feasibility and preliminary efficacy of the intervention through examining participant retention, participant feedback, researcher and participant adherence to protocols, impact on hydration biomarkers, and participant reported GLP - 1 RA side effects.

Who Is on the Research Team?

KN

Katherine N Balantekin, PhD, RD

Principal Investigator

University at Buffalo

EG

Elizabeth G Mietlicki-Baase, PhD

Principal Investigator

University at Buffalo

LH

Leonard H Epstein, PhD

Principal Investigator

University at Buffalo

Are You a Good Fit for This Trial?

This trial is for adults aged 18-60 who have just started a GLP-1 RA medication (within the past week), can speak English, and are willing to follow the study instructions.

Inclusion Criteria

Willing to complete the study protocol
I am between 18 and 60 years old.
I started taking a GLP-1RA medication within the past week.
See 1 more

Exclusion Criteria

I have used a GLP-1RA medication for more than one week.
Not fluent in English
I am over 60 years old.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Run-in

Participants undergo a one-week run-in period to establish baseline measurements

1 week
1 visit (in-person)

Intervention

Participants receive hydration intervention to increase hydration and potentially decrease side effects of GLP-1 RA therapy

16 weeks
Weekly virtual check-ins

Follow-up

Participants are monitored for safety and effectiveness after the intervention

4 weeks

What Are the Treatments Tested in This Trial?

Trial Overview

The study compares increased hydration versus usual care in people starting GLP-1 RA therapy. It lasts 17 weeks, with participants randomly assigned to either drink more fluids or continue as normal, to see if better hydration reduces side effects from the medication.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Hydration PlusExperimental Treatment1 Intervention
Group II: ControlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

State University of New York at Buffalo

Lead Sponsor

Trials
279
Recruited
52,600+

National Institutes of Health (NIH)

Collaborator

Trials
2,896
Recruited
8,053,000+